Literature DB >> 21354800

Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).

Anne Pick1, Henrik Müller, Ralf Mayer, Britta Haenisch, Ilza K Pajeva, Mathias Weigt, Heinz Bönisch, Christa E Müller, Michael Wiese.   

Abstract

Flavonoids are an interesting group of natural products ubiquitously present in human diet. Their consumption has been associated with various and differing beneficial health effects. However, several flavonoids have been reported to inhibit the breast cancer resistance protein (BCRP) encoded by the ABCG2 gene. Thus, the consumption of flavonoids with high inhibitory activity could change pharmacokinetics and drug levels of drugs that are BCRP substrates. In cancer patients receiving chemotherapy an increased intake of such flavonoids could lead to adverse effects. We investigated a structurally diverse set of flavonoids, including derivatives with a rare C-methylated structure that were isolated from plants used in traditional medicine. The flavones retusin and ayanin were found to be highly potent inhibitors of BCRP, showing only slightly less potency than Ko143, the most potent ABCG2 inhibitor known so far. The activity data were analyzed by 2D and 3D QSAR analyses and the results revealed the impact of the different substituents at the various positions of the flavonoid core on activity. Additionally, a lateral 2D QSAR analysis of data collected from the literature was performed aiming to derive more general information about the influence of distinct structural features on the inhibitory potency of flavonoids. The comparative QSAR analyses led to a consistent picture of the effects of the different substituents at various positions of the flavone backbone. The following structural features were found to contribute positively to BCRP inhibition: a hydroxyl group in position 5, double bond between position 2 and 3, and a methoxy group in position 3. The exchange of a 3-methoxy group by an OH-group acting also as a hydrogen bond donor, resulted in decrease in activity underlining the potential role of the hydrogen bond acceptor 3-OCH(3) for the interaction with BCRP.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21354800     DOI: 10.1016/j.bmc.2010.12.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

1.  Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways.

Authors:  Cláudia Alessandra Andrade de Paula; Vivien Jane Coulson-Thomas; Joana Gasperazzo Ferreira; Paloma Korehisa Maza; Erika Suzuki; Adriana Miti Nakahata; Helena Bonciani Nader; Misako Uemura Sampaio; Maria Luiza V Oliva
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 2.  Addressing Facts and Gaps in the Phenolics Chemistry of Winery By-Products.

Authors:  Nelson F L Machado; Raúl Domínguez-Perles
Journal:  Molecules       Date:  2017-02-14       Impact factor: 4.411

Review 3.  Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

Authors:  Kristin M Bircsak; Lauren M Aleksunes
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 4.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

5.  Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways.

Authors:  Wen Jiang; Ming Hu
Journal:  RSC Adv       Date:  2012-09-21       Impact factor: 3.361

6.  The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.

Authors:  Guillermo Moreno-Sanz; Borja Barrera; Ana Guijarro; Ilaria d'Elia; Jon Andoni Otero; Ana I Alvarez; Tiziano Bandiera; Gracia Merino; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2011-07-07       Impact factor: 7.658

Review 7.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

8.  Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.

Authors:  Lan Tang; Ye Li; Wei-Ying Chen; Shan Zeng; Ling-Na Dong; Xiao-Juan Peng; Wen Jiang; Ming Hu; Zhong-Qiu Liu
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

Review 9.  Stevia Genus: Phytochemistry and Biological Activities Update.

Authors:  Jimena Borgo; Laura C Laurella; Florencia Martini; Cesar A N Catalán; Valeria P Sülsen
Journal:  Molecules       Date:  2021-05-06       Impact factor: 4.411

10.  Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions.

Authors:  Alexander Sedykh; Denis Fourches; Jianmin Duan; Oliver Hucke; Michel Garneau; Hao Zhu; Pierre Bonneau; Alexander Tropsha
Journal:  Pharm Res       Date:  2012-12-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.